Advertisement

Breast Cancer Research and Treatment

, Volume 169, Issue 3, pp 407–412 | Cite as

First international TNBC conference meeting report

  • Padmashree Rida
  • Angela Ogden
  • Ian O. Ellis
  • Zsuzsanna Varga
  • Antonio C. Wolff
  • Tiffany A. Traina
  • Christos Hatzis
  • Julie R. Palmer
  • Christine B. Ambrosone
  • Brian D. Lehmann
  • Rita Nanda
  • Valerie Montgomery Rice
  • Otis W. Brawley
  • Mylin A. Torres
  • Emad Rakha
  • Ritu AnejaEmail author
Review

Abstract

Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.

Keywords

Triple negative breast cancer Racial disparities Targeted drugs Immunotherapy Molecular subtypes 

References

  1. 1.
    Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15(4):248–254CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pareja F, Geyer FC, Marchio C, Burke KA, Weigelt B, Reis-Filho JS (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2:16036CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19(19):5533–5540CrossRefPubMedGoogle Scholar
  5. 5.
    Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A et al (2017) Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res 23(18):5561–5572CrossRefPubMedGoogle Scholar
  7. 7.
    Jiang T, Shi W, Natowicz R, Ononye SN, Wali VB, Kluger Y, Pusztai L, Hatzis C (2014) Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genom 15:876CrossRefGoogle Scholar
  8. 8.
    Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L et al (2016) Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis. PLOS Med 13(12):e1002193CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J (2015) Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 68(7):506–510CrossRefPubMedGoogle Scholar
  10. 10.
    Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Teijido P, Cabal ML, Fernandez IP, Perez YF (2016) Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin Med Insights Oncol 10(Suppl 1):31–39PubMedPubMedCentralGoogle Scholar
  12. 12.
    Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA (2013) Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol 44(10):2055–2063CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D et al (2016) Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 69(1):25–34CrossRefPubMedGoogle Scholar
  14. 14.
    Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S (2017) Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016. J Translational Med 15(1):205CrossRefGoogle Scholar
  15. 15.
    Lee S, Cho EY, Park YH, Ahn JS, Im Y-H (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52(1):73–81CrossRefPubMedGoogle Scholar
  16. 16.
    Wang J, Chen H, Chen X, Lin H (2016) Expression of tumor-related macrophages and cytokines after surgery of triple-negative breast cancer patients and its implications. Med Sci Monit 22:115–120CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Palmer JR, Castro-Webb N, Bertrand K, Bethea TN, Denis GV (2017) Type II diabetes and incidence of estrogen receptor negative breast cancer in African American women. Cancer Res 77(22):6462–9.  https://doi.org/10.1158/0008-5472.CAN-17-1903 CrossRefPubMedGoogle Scholar
  18. 18.
    Mahamodhossen YA, Liu W, Rong-Rong Z (2013) Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol (Northwood Lond Engl) 30(3):653CrossRefGoogle Scholar
  19. 19.
    Lee A, Djamgoz MBA (2018) Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62:110–122CrossRefPubMedGoogle Scholar
  20. 20.
    Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J et al (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13(4):890–901CrossRefPubMedGoogle Scholar
  21. 21.
    De Michele A, Harding JJ, Telli ML, Munster PN, McKay R, Iliopoulos O, Orford KW, Bennett MK, Mier JW, Owonikoko TK et al (2016) Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol 34(15_suppl):1011CrossRefGoogle Scholar
  22. 22.
    Strekalova E, Malin D, Good DM, Cryns VL (2015) Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL receptor-2 expression. Clin Cancer Res 21(12):2780–2791CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G (2016) New strategies in breast cancer: immunotherapy. Clin Cancer Res 22(9):2105–2110CrossRefPubMedGoogle Scholar
  24. 24.
    Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M et al (2017) Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat.  https://doi.org/10.1007/s10549-017-4537-5 PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Howlader NNA, Krapcho M et al (2015) SEER cancer statistics review, 1975–2012. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015, National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/csr/1975_2012/
  26. 26.
    Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I et al (2018) Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 68(1):31–54CrossRefPubMedGoogle Scholar
  27. 27.
    Hunt BR, Hurlbert MS (2016) Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005–2014. Cancer Epidemiol 45:169–173CrossRefPubMedGoogle Scholar
  28. 28.
    Braveman P (2014) What are health disparities and health equity? We need to be clear. Public Health Rep 129(Suppl 2):5–8CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Newman LA, Kaljee LM (2017) Health disparities and triple-negative breast cancer in african american women: a review. JAMA Surg 152(5):485–493CrossRefPubMedGoogle Scholar
  30. 30.
    Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T et al (2017) Biology and etiology of young-onset breast cancers among premenopausal african american women: results from the AMBER Consortium. Cancer Epidemiol Biomark Prev 26(12):1722–1729CrossRefGoogle Scholar
  31. 31.
    Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, Tang L, Hu Q, Freudenheim JL, Shields PG et al (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5(1):237–248CrossRefPubMedGoogle Scholar
  32. 32.
    Espinal AC, Buas MF, Wang D, Cheng DT-Y, Sucheston-Campbell L, Hu Q, Yan L, Payne-Ondracek R, Cortes E, Tang L et al (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166(2):559–568CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Padmashree Rida
    • 1
    • 2
  • Angela Ogden
    • 1
  • Ian O. Ellis
    • 3
  • Zsuzsanna Varga
    • 4
  • Antonio C. Wolff
    • 5
  • Tiffany A. Traina
    • 6
    • 7
  • Christos Hatzis
    • 8
  • Julie R. Palmer
    • 9
  • Christine B. Ambrosone
    • 10
  • Brian D. Lehmann
    • 11
  • Rita Nanda
    • 12
  • Valerie Montgomery Rice
    • 13
  • Otis W. Brawley
    • 14
  • Mylin A. Torres
    • 15
    • 16
  • Emad Rakha
    • 3
  • Ritu Aneja
    • 1
    Email author return OK on get
  1. 1.Department of BiologyGeorgia State UniversityAtlantaUSA
  2. 2.Novazoi TheranosticsRolling Hills EstatesUSA
  3. 3.Department of Histopathology, Nottingham City Hospital NHS TrustNottingham UniversityNottinghamUK
  4. 4.Department of Pathology and Molecular PathologyUniversity Hospital ZurichZurichSwitzerland
  5. 5.The Johns Hopkins Kimmel Comprehensive Cancer CenterBaltimoreUSA
  6. 6.Breast Medicine ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  7. 7.Weill Cornell MedicineNew YorkUSA
  8. 8.Department of Medicine, Breast Medical Oncology, Yale School of MedicineYale UniversityNew HavenUSA
  9. 9.Slone Epidemiology CenterBoston UniversityBostonUSA
  10. 10.Department of Cancer Prevention and ControlRoswell Park Comprehensive Cancer CenterBuffaloUSA
  11. 11.Department of BiochemistryVanderbilt UniversityNashvilleUSA
  12. 12.Section of Hematology-Oncology, Department of MedicineThe University of ChicagoChicagoUSA
  13. 13.Morehouse School of MedicineAtlantaUSA
  14. 14.American Cancer SocietyAtlantaUSA
  15. 15.Department of Radiation OncologyEmory UniversityAtlantaUSA
  16. 16.Glenn Family Breast Center, Winship Cancer InstituteEmory UniversityAtlantaUSA

Personalised recommendations